Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344852 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL337876 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL337914 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL334606 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL16539029 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL336557 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL4821245 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL18378739 | 0.99 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL24819248 | 0.93 | KMT2A (0.44) | KMT2ANOD1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL20467657 | 0.93 | KMT2A (0.44) | KMT2ANOD1POLBL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110023329-B | Novel compounds as peptide triple GLP 1/glucagon/GIP receptor agonists | 赛诺菲 | 2024-05-03 | — | — | CN | disclosed |
| CN-116836258-A | Solid phase synthesis method of liraglutide | 辽宁药联制药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3548508-B1 | NEW COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI SA (FR) | 2021-10-27 | — | — | EP | disclosed |
| CN-111892650-A | Solid-phase synthesis method of liraglutide | 辽宁药联制药有限公司 | 2020-11-06 | — | — | CN | disclosed |
| CN-110023329-A | Noval chemical compound as the triple GLP1/ glucagon/GIP receptor stimulating agents of peptides | 赛诺菲 | 2019-07-16 | — | — | CN | disclosed |
| US-20190177392-A1 | SYNTHESIS OF GLP-1 PEPTIDES | NOVETIDE LTD (IL) | 2019-06-13 | — | — | US | disclosed |
| US-20180155406-A1 | COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI (FR) | 2018-06-07 | — | — | US | disclosed |
| US-20180057558-A1 | Synthesis of GLP-1 Peptides | NOVETIDE, LTD. (IL) | 2018-03-01 | — | — | US | disclosed |
| EP-3221342-A1 | SYNTHESIS OF GLP-1 PEPTIDES | Novetide Ltd. (IL) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016046753-A1 | SYNTHESIS OF GLP-1 PEPTIDES | NOVETIDE, LTD. (IL) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177392-A1 | SYNTHESIS OF GLP-1 PEPTIDES | GLP1R, GIPR, IAPP | KMT2A 2774/4885NOD1 365/4885POLB 3820/4885 |
| US-20180057558-A1 | Synthesis of GLP-1 Peptides | GLP1R, GIPR, IAPP | KMT2A 2774/4885NOD1 365/4885POLB 3820/4885 |
| US-20180155406-A1 | COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | KMT2A 4117/4885NOD1 1688/4885POLB 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.